



INTEGRATED PROTEINS LIMITED

Manek Centre, Office No 218, P N Marg, Jamnagar – 361008, Gujarat, India

Phone: 9428817400

Email ID: integrated.pl2024@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

Date: 27-05-2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001

Scrip Code: 519606

Subject: Submission of Revised Audited Financial Results for the Quarter and Financial Year Ended March 31, 2026

Dear Sir/Madam,

This is with reference to the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026, which were approved by the Board of Directors and duly submitted to the Exchange on May 26, 2026. Subsequent to the aforesaid submission, it was observed that due to an inadvertent oversight, provision for taxation had remained to be accounted for in the financial results submitted earlier. Consequently, certain financial figures required revision. Accordingly, upon incorporating the requisite provision for taxation:

- The Net Profit stands revised to Rs. 19.00 Lakhs as against Rs. 23.14 Lakhs reported earlier; and
- The Earnings Per Share (EPS) stands revised to Rs. 0.10 as against Rs. 0.13 reported earlier.

The aforesaid revised financial results were placed and approved by the Board of Directors of the Company in their meeting which started at 7:30 pm and concluded at 8:00 pm. In compliance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the revised Audited Financial Results for the quarter and financial year ended March 31, 2026 for your kind record and dissemination.

We sincerely regret the inadvertent error and request you to kindly take the revised financial results on record.

Thanking you,
For Integrated Proteins Limited

Karanj Dharmeshbhai Doshi
Managing Director
DIN:10848249

INTEGRATED PROTEINS LIMITED

CIN: L62013GJ1992PLC018426

REGISTERED OFFICE: Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Gujarat, India, 361008

Standalone Statement of Audited Financial Results for the Quarter/ Year Ended 31-03-2026

(Rs. In Lakh except per share data)





Particulars	Quarter Ended			Year Ended	Year Ended
	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
A	01-01-2026	01-10-2025	01-01-2025	01-04-2025	01-04-2024
B	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
C	Whether results are audited or unaudited	Audited	Unaudited	Audited	Audited
Part I					
I Revenue From Operations					
Net sales or Revenue from Operations	569.03	-	2,148.67	993.57	2,149.63
II Other Income	0.50	-	3.89	0.50	23.74
III Total Income (I + II)	569.53	-	2,152.56	994.07	2,173.37
IV Expenses					
(a) Cost of materials consumed	-	-	-	-	-
(b) Purchases of stock-in-trade	542.74	-	2,102.50	950.14	2,102.50
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
(d) Employee benefit expense	0.54	0.60	-	3.16	1.63
(e) Finance Costs	-	-	-	-	-
(f) Depreciation and amortisation expense	-	-	-	-	0.96
(g) Other Expenses	3.11	0.95	22.65	12.43	36.33
Total expenses	546.39	1.55	2,125.15	965.74	2,141.42
V Profit (loss) before Exceptional and Extraordinary Items and	23.14	(1.55)	27.41	28.33	31.95
VI Exceptional Items					
VIII Profit (loss) before Tax (VII-VIII)	23.14	(1.55)	27.41	28.33	31.95
X Tax Expense					
(a) Current Tax	4.14	-	6.90	5.83	8.04
(Less):- MAT Credit	-	-	-	-	-
Current Tax Expense Relating to Prior years	-	-	-	-	-
(b) Deferred Tax (Asset)/Liabilities	-	-	(0.79)	-	(1.10)
XI Net Profit/Loss for the period from Continuing Operations (IX-X)	19.00	(1.55)	21.30	22.50	25.00
XII Profit (Loss) from Discontinuing Operations	-	-	-	-	-
XIII Tax Expenses of Discontinuing Operations	-	-	-	-	-
XIV Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)	-	-	-	-	-
XV Profit (Loss) for the period (XI+XIV)	19.00	(1.55)	21.30	22.50	25.00
XVI Other Comprehensive Income					
a. i). Amount of item that will not be reclassified to profit or loss					
ii). Income tax relating to items that will not be reclassified to profit or loss					
b. i). Item that will be reclassified to profit or loss					
ii). Income tax relating to items that will be reclassified to profit or loss					
XVII Total Comprehensive income	0.00	0.00	0.00	0.00	0.00
Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)	19.00	(1.55)	21.30	22.50	25.00
XVIII Details of equity share capital					
Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	1,871.36	1,871.36	352.02	1,871.36	352.02
Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX Earnings per share (Not Annualised for Quarters)	0.10	(0.01)	0.11	0.12	0.13
(a) Earnings per share Continuing Operation (Not Annualised for Quarters)					
Basic earnings per share before extraordinary items	0.10	(0.01)	0.11	0.12	0.13
Diluted earnings per share before extraordinary items	0.10	(0.01)	0.11	0.12	0.13
(b) Earnings per share Discontinuing Operation (Not Annualised for Quarters)					
Basic earnings per share after extraordinary items	0.00	0.00	0.00	0.00	0.00
Diluted earnings per share after extraordinary items	0.00	0.00	0.00	0.00	0.00
(c) Earnings per share (Not Annualised for Quarters)					
Basic earnings per share before extraordinary items	0.10	(0.01)	0.11	0.12	0.13
Diluted earnings per share before extraordinary items	0.10	(0.01)	0.11	0.12	0.13

* Basic and Diluted Earnings per share are not annualised except for the year ended 31, March 2026.

Notes:-

Notes to Standalone Audited financials results for the year ended 31st March 2026:

- 1 The above audited standalone financial results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on May 26 2026. The statutory auditors have expressed an unmodified opinion.
- 2 The above Audited financial results have been prepared in accordance with Companies (Accounting Standards) Rules, 2006 (AS) as amended, prescribed under Section 129 to 133 of Companies Act, 2013, read with relevant rules.

3	The Company has multiple reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
4	The results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 33- Earning per Share, considering the Company has during the year ended 31st March 2026 has received share application money and has allotted the same.
5	Statement of Assets and Liabilities and cashflow statement as on 31st March 2026 is enclosed herewith.
6	The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.
<p>Date :- 26-05-2026 Place :- Jamnagar</p> <p style="text-align: right;"> FOR Integrated Proteins Limited  Karan Dharmeshbhai Desai Managing Director DIN: 10848249 </p> <p style="text-align: center;">  CS Girish Kalwani Company Secretary M.No - AS7701 </p> <p style="text-align: right;">  Manish Choudhary CFO </p> 	

INTEGRATED PROTEINS LIMITED

CIN: L62013GJ1992PLC018426

REGISTERED OFFICE: Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Gujarat, India,

(Rupees in Lakhs)

Standalone Statement of Balance Sheet as at 31st March, 2026

Particulars	As at	As at
	31st March, 2026	31st March, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	4.64	4.64
(b) Capital work-in-progress	-	-
(c) Other Intangible Assets		
(d) Financial assets	-	-
(i) Investments	0.03	0.03
(ii) Trade receivables		
(iii) Loan		
(e) Deferred Tax Assets	-	-
(f) Other non-current asset	-	0.70
	-	-
Total non-current assets	4.67	5.38
Current assets		
(a) Inventories	-	-
(b) Financial assets		
(i) Trade receivables	206.25	
(ii) Cash and cash equivalents	(1.56)	8.73
(iii) Loan		
(iv) Other financial asset		
(c) Income/Current tax assets (net)		
(c) Other current assets	1,851.72	3,223.12
Total current assets	2,056.41	3,231.85
TOTAL ASSETS	2,061.08	3,237.23
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,903.02	352.02
(b) Other equity	149.64	1,659.79
Total equity	2,052.66	2,011.81
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings		
(b) Deferred tax liability (net)		
Total non current liabilities		
Current liabilities		
(a) Financial liabilities		
(i) Borrowings		389.55
(ii) Trade payable		
1. Dues of micro enterprises and small enterprises		
2. Dues of creditor other than micro enterprises and small enterprises		800.31
(iii) Other financial liabilities		
(b) Provision		
(c) Income/Current tax liabilities (net)		
(d) Other current liabilities	8.42	35.56
Total current liabilities	8.42	1,225.43
TOTAL EQUITY AND LIABILITIES	2,061.08	3,237.23

Date :- 26-05-2026
Place :- Jamnagar

FOR, Integrated Proteins Limited

Karan Dharamesh Chhalani
Managing Director
DIN: 10848249



(Signature)

CS Girish Kalwani
Company Secretary
M.No- A57701

(Signature)

Manish Mungra
CFO

INTEGRATED PROTEINS LIMITED

CIN: L62013GJ1992PLC018426

REGISTERED OFFICE: Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Gujarat, India,


(Rupees in Lakhs)

Standalone Cash Flow Statement for the year ended 31st March 2026

S.No.	Particulars	Year ended 31st March, 2026	Year ended 31st March, 2025
A)	Cash flow from operating activities		
	Profit before taxation	28.33	31.94
	Adjustment for :	-	-
	Depreciation and amortisation	-	0.96
	Finance cost	-	-
	Interest income	-	(15.30)
	Profit on Sale of Fixed Assets	-	(6.70)
	Adjustment for Previous year	-0.64	-
	Dividend Income	-	-
	Operating profit/(loss) before working capital changes	27.69	10.90
	Adjustment for :		
	Increase/ (Decrease) in trade payables	-800.32	799.02
	Increase/ (Decrease) in other current liabilities	-27.13	28.56
	Decrease/ (Increase) in other current Assets	1371.39	(3,219.34)
	Decrease/ (Increase) in Loan & Advances	-	32.39
	Decrease/ (Increase) other current assets	0.7	-
	Decrease/ (Increase) in trade receivables	-206.24	-
	Provision	-	-
		338.40	(2,359.37)
	Cash Generated from operations	366.09	(2,348.47)
	Taxes paid (net)	5.83	8.04
	Net cash flow from/(used in) operating activities (A)	360.26	(2,356.51)
B)	Cash from investing activities		
	Movements in Investments	0	15.26
	Sale of property, plant and equipment	0	42.60
	Purchase of property, plant and equipment	0	-
	Movements in Other Non current Assets	0	174.00
	Interest income	0	15.30
	Net cash used in investing activities (B)	-	247.16
C)	Cash flow from financing activities		
	Issue of share capital	19	1,725.87
	Proceeds from long-term borrowings	-	(3.50)
	Proceeds from short-term borrowings	-389.55	389.55
	Finance cost paid	-	-
	Net cash flow from financing activities (C)	(370.55)	2,111.92
D)	Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(10.29)	2.58
E)	Cash and cash equivalents as at the beginning of the year	8.73	6.15
F)	Cash and cash equivalents as at the end of the year	(1.56)	8.73
	Balance with banks	-9.44	1.02
	Cash in hand	7.88	7.71
	Total	-1.56	8.73

Date :- 26-05-2026
Place :- Jamnagar

FOR Integrated Proteins Limited

Karanj Dharmeshbhai Doshi
Managing Director
DIN: 10848249CS Girish Kalwani
Company Secretary
M.No- A57701Manish Mungra
CFO

INTEGRATED PROTEINS LIMITED

CIN:L62013GJ1992PLC018426


Registered Office : Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Jamnagar, Gujarat, India, 361008

Reporting of Segment wise Revenue, Results and Capital Employed along financial results for the Quarter and Year ended on
March 31, 2026

(₹ In Lakh except per share data)

Particulars	Quarter ended		Year to date Figures	Year to date Figures
	31/03/2026	31/03/2025	31-03-2026	31-03-2025
A Date of start of reporting period	01-01-2026	01-01-2025	01-04-2025	01-04-2024
B Date of end of reporting period	31/03/2026	31/03/2025	31-03-2026	31-03-2025
C Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D Nature of report standalone or consolidated	STANDALONE	STANDALONE	STANDALONE	STANDALONE
1 Segment Revenue (net sale/income from each segment should be disclosed under this head)				
(a) Segment - Agro&Trading	17.78	2,149.62	437.60	2,149.62
(b) Segment - Textile	461.63		461.62	
(C) Segment- Securities	89.62		94.34	
(d) Segment- Medical	0.50		0.50	
(e) Segment - Real estate	-	-	-	-
Total	569.53	2,149.62	994.06	2,149.62
Less: Inter Segment Revenue	-	-	-	-
Net sales/Income From Operations	569.53	2,149.62	994.06	2,149.62
2 Segment Results (Profit)(+)/ Loss (-) before tax and interest from Each segment)#				
(a) Segment - Agro&Trading	0.81	47.12	13.22	47.12
(b) Segment - Textile	5.24		5.24	
(C) Segment- Securities	19.89	(0.03)	23.98	(0.81)
(d) Segment- Medical	0.50		0.50	
(e) Segment - Real estate	-	-	-	-
(f) Unallocable		4.85		24.05
Total	26.44	51.94	42.94	70.36
Finance Cost	3.30	25.00	14.61	37.80
Other Un-allocable Expenditure net off	-	-	-	0.96
Un-allocable income	3.30	25.00	14.61	36.84
Total Profit Before Tax	23.14	26.94	28.33	32.56
3 Capital Employed (Segment assets - Segment Liabilities)				
3(1) Segment Assets				
(a) Segment - Agro&Trading	26.18	5.34	26.18	5.34
(b) Segment Textile	184.70		184.70	
(c) Segment- Securities	1,531.32	2,136.36	1,531.32	2,136.36
(d) Segment- Medical	150.00		150.00	
(e) Segment - Real estate	150.54	1,058.49	150.54	1,058.49
(g) Unallocable	15.53	(354.01)	15.53	(354.01)
Total	2,058.27	2,846.20	2,058.27	2,846.20
3(2) Segment Liabilities				
(a) Segment - Agro&Trading	-	-	-	-
(b) Segment Textile				
(c) Segment- Securities				
(d) Segment- Medical				
(e) Segment - Real estate				
(g) Unallocable	15.63	834.40	15.63	834.40
Total	15.63	834.40	15.63	834.40

For, Integrated Proteins Limited


 Karanj Dharmeshbhai Joshi
 Managing Director
 DIN:10848249


 CS Girish Kalwani
 Company Secretary
 MNo- A57701


 Manish Mungra
 CFO

Date :-26-05-2026
Place:- Jamnagar





INDEPENDENT AUDITOR'S REPORT

To Board of Directors of
Integrated Proteins Limited

Independent Auditors Report on the Quarter and Year to date standalone financial results of Integrated Proteins Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015

Opinion

1. We have audited the accompanying standalone financial results of **Integrated Proteins Limited** (hereinafter referred to as "the company") for the year ended March 31, 2026 and the standalone statement of assets and liabilities and standalone statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('listing regulations').
2. In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) give a true and fair view in conformity with recognition and measurement principles laid down in applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") and other accounting principles generally accepted in India, of the net profit (including other comprehensive income) and other financial information of the company for the year ended March 31, 2026, and the standalone statement of assets and liabilities and standalone statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India ("the ICAI"). Our responsibilities under those standards are further described in the 'Auditor's Responsibilities for the Audit of Standalone Financial Results' section of our report. We are independent of the company in accordance with the code of ethics issued by the ICAI together with ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and Rules made thereunder, and we have fulfilled our ethical responsibilities in accordance with the requirements with these requirements and the Code of Ethics. We believe that the audit evidences obtained by us is sufficient and appropriate to provide a basis for our opinion.



Board of Directors' Responsibilities for the Standalone Financial Results

4. These standalone financial results have been prepared on the basis of the annual standalone financial statements. The company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the company and the standalone statement of assets and liabilities and standalone statement of cash flows in accordance with recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant issues thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of accounting policies; making judgement and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give true and fair view and are free for material misstatement, whether due to fraud and error.
5. In preparing the standalone financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company is responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of Standalone Financial Results

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from a fraud or error and consider material, if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
8. As part of an audit in accordance with the SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedure responsive to those risks, and obtain audit evidence that is sufficient and appropriate to our basis of opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud involves collusions, forgery, intentional omissions, misrepresentations, or override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of the accounting policies used and reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on our audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidences obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of financial results including the disclosures and whether the standalone financial results represent the underlying transactions and events in the manner that achieves fair presentation.
9. We communicate with those charged with governance of the company regarding, among other matters, the planned scope of timing of the audit and significant audit findings, including significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear our independence, and wherever applicable, related safeguards.



B.B. Gusani & Associates
Chartered Accountants

CA BHARGAV B. GUSANI
M bhargavgusani77@gmail.com

Other Matters

10. The Statement include the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For, B B Gusani and Associates
Chartered Accountants

Bhargav B Gusani

Proprietor

Membership No. 120710

FRN: 140785W


UDIN: 26120710NRTGPR2730

Date: 26/05/2026

Place: Jamnagar



Office Address: 215, Manek Centre, P.N. Marg,
Jamnagar - 361 008 (Gujarat) India.



INTEGRATED PROTEINS LIMITED

Manek Centre, Office No 218, P N Marg, Jamnagar - 361008, Gujarat, India

Phone- 9428817400

Email ID: integrated.pl2024@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC: Not Applicable

C. DISCLOSURE OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: Not Applicable

Sr. No	Particulars	In INR Crore
1	Loans / revolving facilities like cash credit from banks / financial institutions 0	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on Date	0
3	Total financial indebtedness of the listed entity including short-term and long-term debt	0

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS : Not Applicable as there is no related party transaction.

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH AUDITED FINANCIAL RESULTS : Not Applicable

For , Integrated Proteins Limited



KARANJ DHARMESHWAR DOSHI
MANAGING DIRECTOR
DIN:10848249



INTEGRATED PROTEINS LIMITED

Manek Centre, Office No 218, P N Marg, Jamnagar – 361008, Gujarat, India

Phone :9428817400

Email ID: integrated.pl2024@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

Date: 26-05-2026

To,
Department of Corporate Service
BSE Limited
Phiroz Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Dear Sir/Madam,

DECLARATION

I, Karanj Dharmeshbhai Doshi, Managing Director of Integrated Proteins Limited having its registered office at Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Jamnagar, Gujarat, India, 361008, India hereby declare that, the Statutory Auditors of the Company, B B Gusani & Co., Chartered Accountants, Ahmedabad {FRN: 140785W} have issued an Audit Report with unmodified opinion on Audited Financial Results for the quarter and year ended on 31st March, 2026.

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated 25th May, 2016.

For, Integrated Proteins Limited

KARANJ DHARMESHBHAI DOSHI
MANAGING DIRECTOR
DIN:10848429